BAY 1135626 用于合成 BAY 1129980，用于抗肿瘤研究。BAY 1129980 是一种基于 Auristatin 的 ADC 试剂，具有抗 C4.4A (LYPD3) 作用，可用于非小细胞肺癌 (NSCLC) 的研究。 在溶剂中：-80°C，6个月-20°C，1个月（避光） BAY 1135626 is used to synthesize BAY 1129980 for anti-tumor research. BAY 1129980 is an ADC reagent based on Auristatin, which has anti-C4.4A (LYPD3) activity and can be used for research on non-small cell lung cancer (NSCLC). In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) In vitro research C4.4A (LYPD3) is a protein expressed in non-small cell lung cancer (NSCLC), with scarcely expressing in normal tissues.BAY 1135626 can be synthesized into BAY 1129980 (C4.4A-ADC), shows a strong anti-proliferative effect on C4.4A expressing cell lines.BAY 1129980 (0.001-100 nM; 72 h) inhibits the proliferation of A549 lung cancer cell lines transfected with C4.4A.BAY 1129980 (0.001-100 nM; 72 h) exhibits high and selective efficacy on hC4.4A:A549 cells in vitro. In vivo research BAY 1129980 (1.9-7.5 mg/kg; i.v.; 20 d) inhibits tumor growth in vivo in mouse.BAY 1129980 with a repeated dosing (15 mg/kg; i.v.; 21 d for 1st cycle and 57 d for 2nd cycle) is well tolerated without changing the sensitivity to the treatment.